Literature DB >> 3783031

Morphometric evaluation of thrombogenesis by microvesicles from human tumor cell lines with thrombin-dependent (U87MG) and adenosine diphosphate-dependent (SKNMC) platelet-activating mechanisms.

E Bastida, G Escolar, A Ordinas, G A Jamieson.   

Abstract

The Baumgartner perfusion apparatus has been used for quantitative comparison of the interaction of platelets with subendothelium in the presence of microvesicles derived from SKNMC (human neuroblastoma) cells, which aggregate platelets by an adenosine diphosphate (ADP)-dependent mechanism, and U87MG (human glioblastoma) cells, which function by a thrombin-dependent mechanism. The derived microvesicles from each line were as effective as the intact cells in inducing thrombogenesis on both undigested and alpha-chymotrypsin-digested subendothelium. Thrombus size on digested vessels was greater than on undigested vessels by fivefold for SKNMC cells and microvesicles and by 20-fold for U87MG cells and sevenfold for U87MG microvesicles. The results show that microvesicles from both cell lines initiate interactions between platelets and subendothelium identical to those caused by intact tumor cells. The results also demonstrate that intact tumor cells in the circulation may not be necessary for the thromboembolic complications of malignancy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3783031

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  9 in total

1.  Addition of both platelets and thrombin in combination accelerates tumor cells to adhere to endothelial cells in vitro.

Authors:  I B Helland; B Klementsen; L Jørgensen
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-03       Impact factor: 2.416

2.  Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.

Authors:  Carlos Medina; Shona Harmon; Iwona Inkielewicz; Maria Jose Santos-Martinez; Michael Jones; Paula Cantwell; Despina Bazou; Mark Ledwidge; Marek W Radomski; John F Gilmer
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 3.  Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation.

Authors:  Paul Jurasz; David Alonso-Escolano; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2004-10-18       Impact factor: 8.739

4.  Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung.

Authors:  Tatjana M H Niers; Lois W Brüggemann; Clara P W Klerk; Femke J M Muller; Tessa Buckle; Pieter H Reitsma; Dick J Richel; C Arnold Spek; Olaf Van Tellingen; Cornelis J F Van Noorden
Journal:  Clin Exp Metastasis       Date:  2008-12-10       Impact factor: 5.150

5.  Role of ADP receptors on platelets in the growth of ovarian cancer.

Authors:  Min Soon Cho; Kyunghee Noh; Monika Haemmerle; Dan Li; Hyun Park; Qianghua Hu; Takeshi Hisamatsu; Takashi Mitamura; Sze Ling Celia Mak; Satya Kunapuli; Qing Ma; Anil K Sood; Vahid Afshar-Kharghan
Journal:  Blood       Date:  2017-07-05       Impact factor: 22.113

Review 6.  Interaction between circulating cancer cells and platelets: clinical implication.

Authors:  Xiao-Liang Lou; Jian Sun; Shu-Qi Gong; Xue-Feng Yu; Rui Gong; Huan Deng
Journal:  Chin J Cancer Res       Date:  2015-10       Impact factor: 5.087

Review 7.  Hemostatic changes in patients with brain tumors.

Authors:  L Thoron; E Arbit
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

8.  Targeting Activated Platelets: A Unique and Potentially Universal Approach for Cancer Imaging.

Authors:  May Lin Yap; James D McFadyen; Xiaowei Wang; Nicholas A Zia; Jan David Hohmann; Melanie Ziegler; Yu Yao; Alan Pham; Matthew Harris; Paul S Donnelly; P Mark Hogarth; Geoffrey A Pietersz; Bock Lim; Karlheinz Peter
Journal:  Theranostics       Date:  2017-06-25       Impact factor: 11.556

Review 9.  Phosphatidylserine is an overlooked mediator of COVID-19 thromboinflammation.

Authors:  Stuart E Lind
Journal:  Heliyon       Date:  2021-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.